Clarke RB - Search Results

1

Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.

Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, Papaikonomou K, Jones L, Herzog C, Pashayan N, Simões BM, Clarke RB, Evans DG, Ghezelayagh TS, Ponandai-Srinivasan S, Boggavarapu NR, Lalitkumar PG, Howell SJ, Risques RA, Rådestad AF, Dubeau L, Gemzell-Danielsson K, Widschwendter M. Bartlett TE, et al. Among authors: clarke rb. Genome Med. 2022 Jun 15;14(1):64. doi: 10.1186/s13073-022-01063-5. Genome Med. 2022. PMID: 35701800 Free PMC article. Clinical Trial.

2

Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.

Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E. Clarke RB, et al. Br J Cancer. 1993 Mar;67(3):606-11. doi: 10.1038/bjc.1993.111. Br J Cancer. 1993. PMID: 8439511 Free PMC article. Clinical Trial.

3

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations.

Bramley M, Clarke RB, Howell A, Evans DG, Armer T, Baildam AD, Anderson E. Bramley M, et al. Among authors: clarke rb. Br J Cancer. 2006 Apr 10;94(7):1021-8. doi: 10.1038/sj.bjc.6603042. Br J Cancer. 2006. PMID: 16538216 Free PMC article.

4

Origins of breast cancer subtypes and therapeutic implications.

Sims AH, Howell A, Howell SJ, Clarke RB. Sims AH, et al. Among authors: clarke rb. Nat Clin Pract Oncol. 2007 Sep;4(9):516-25. doi: 10.1038/ncponc0908. Nat Clin Pract Oncol. 2007. PMID: 17728710 Review.

5

Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity.

Howell SJ, Anderson E, Hunter T, Farnie G, Clarke RB. Howell SJ, et al. Among authors: clarke rb. Breast Cancer Res. 2008;10(4):R68. doi: 10.1186/bcr2129. Epub 2008 Aug 5. Breast Cancer Res. 2008. PMID: 18681966 Free PMC article.

6

Are stem-like cells responsible for resistance to therapy in breast cancer?

O'Brien CS, Farnie G, Howell SJ, Clarke RB. O'Brien CS, et al. Among authors: clarke rb. Breast Dis. 2008;29:83-9. doi: 10.3233/bd-2008-29109. Breast Dis. 2008. PMID: 19029627 No abstract available.

7

Resistance to endocrine therapy: are breast cancer stem cells the culprits?

O'Brien CS, Howell SJ, Farnie G, Clarke RB. O'Brien CS, et al. Among authors: clarke rb. J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):45-54. doi: 10.1007/s10911-009-9115-y. Epub 2009 Feb 28. J Mammary Gland Biol Neoplasia. 2009. PMID: 19252972 Review.

8

Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.

Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB. Harrison H, et al. Among authors: clarke rb. Cancer Res. 2010 Jan 15;70(2):709-18. doi: 10.1158/0008-5472.CAN-09-1681. Epub 2010 Jan 12. Cancer Res. 2010. PMID: 20068161 Free PMC article.

9

Breast cancer stem cells and their role in resistance to endocrine therapy.

O'Brien CS, Farnie G, Howell SJ, Clarke RB. O'Brien CS, et al. Among authors: clarke rb. Horm Cancer. 2011 Apr;2(2):91-103. doi: 10.1007/s12672-011-0066-6. Horm Cancer. 2011. PMID: 21761332 Free PMC article. Review.

10

Lack of caveolin-1 (P132L) somatic mutations in breast cancer.

Ferraldeschi R, Latif A, Clarke RB, Spence K, Ashton G, O'Sullivan J, Evans DG, Howell A, Newman WG. Ferraldeschi R, et al. Among authors: clarke rb. Breast Cancer Res Treat. 2012 Apr;132(3):1185-6. doi: 10.1007/s10549-012-1981-0. Epub 2012 Feb 7. Breast Cancer Res Treat. 2012. PMID: 22310961 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

168 results

Search Page